Actively Recruiting

Phase 1
Age: 18Years - 85Years
FEMALE
ID06907199

Daily Nitrofurantoin Versus Bladder Electrofulguration Plus Daily Nitrofurantoin for Long-term Management of Chronic Cystitis in Women With Recurrent Urinary Tract Infections

Led by University of Texas Southwestern Medical Center · Updated on 2026-05-01

104

Participants Needed

2

Research Sites

30 weeks

Total Duration

On this page

Sponsors

U

University of Texas Southwestern Medical Center

Lead Sponsor

U

University of Texas

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying women aged 18 to 85 who have a history of recurrent urinary tract infections (rUTIs) lasting at least one year. The trial aims to compare the effectiveness of daily Nitrofurantoin (NF) antibiotic alone versus a combination of bladder electrofulguration (EF) plus daily Nitrofurantoin for managing early stages of chronic cystitis, a type of bladder inflammation. This is a randomized, multicenter clinical trial involving participants diagnosed with stages 1 or 2 chronic cystitis based on office cystoscopy. Participants will be randomly assigned to one of two groups: one group will receive daily Nitrofurantoin antibiotic for 6 months, and the other will receive the same antibiotic treatment combined with bladder electrofulguration. The study will track the effects of these treatments over a 30-month period. Electrofulguration is a procedure used alongside the antibiotic to potentially improve treatment outcomes in early chronic cystitis. During the study, participants will attend 8 compensated visits at urology clinics to monitor their progress. Researchers will assess treatment success by tracking cystitis symptoms, urine cultures, antibiotic resistance, symptom scores, quality of life, and recurrence rates over 30 months. Safety and symptom assessments will be conducted regularly to understand the long-term effects of each treatment approach.

CONDITIONS

Brief Title

Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections

Who Can Participate

Age: 18Years - 85Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female aged 18 to 85 years
  • History of culture-documented uncomplicated recurrent urinary tract infections for at least 1 year
  • Diagnosis of recurrent UTI defined as 3 or more symptomatic infections in 12 months or 2 or more in 6 months
  • Currently free from UTI symptoms with a negative urine culture (<10^3 colony forming units per ml)
  • Negative upper and lower urinary tract evaluation including pelvic exam, post-void residual less than 50 ml, and imaging to exclude kidney stones or other abnormalities
  • Office cystoscopy confirming stage 1 or 2 chronic cystitis
  • Likely to remain in geographic region for study duration
  • ASA class II or less
Not Eligible

You will not qualify if you...

  • Current use of antibiotics at baseline for suppressive or non-urinary infections
  • Use of self-start antibiotic therapy for urinary symptoms
  • Recent or planned prophylactic antibiotic use within 3 months before or 12 months after enrollment
  • Complicated urinary tract infections including neurogenic bladder, bladder augmentation, or urinary diversion
  • Presence of urinary catheters
  • Uncontrolled diabetes (HbA1c >9)
  • Pregnancy
  • Allergy or resistance to Nitrofurantoin
  • Chronic lung or liver conditions preventing Nitrofurantoin use
  • Chronic renal insufficiency (creatinine over 1.5 g/dl or GFR less than 40)
  • History of chronic diarrhea needing regular therapy
  • Psychosis, dementia, swallowing disorders, or inability to take Nitrofurantoin reliably at home
  • Body mass index over 40
  • Use of Uromune or other vaccines to reduce recurrent UTIs
  • Participation in investigational product research within past 12 weeks
  • Current phage therapy
  • Diagnosis of interstitial cystitis
  • Medical conditions requiring excessive fluid intake

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 6 months

Participants receive daily Nitrofurantoin antibiotic prophylaxis for 6 months, with some also undergoing bladder electrofulguration as part of their treatment.

8 visits over 30 months including treatment and follow-up assessments

Follow-up

Duration - Up to 30 months after enrollment

Participants are monitored to assess the long-term effectiveness and safety of the treatment for up to 30 months after enrollment.

Included in the total of 8 visits over 30 months

Trial Site Locations

Total: 2 locations

1

The University of Kansas

Kansas City, Kansas, United States, 66160

Not Yet Recruiting

2

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

Loading map...

Research Team

M

Meghan Leak

P

Philippe Zimmern, M.D.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Randomized Trial of D-mannose for Preventing Recurrent Urina...

Recurrent UTIs

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here